Redefining CDMO Partnerships Through EnzeneX™ 2.0 and Fully-Connected Continuous Manufacturing™

The biotech industry is undergoing rapid transformation – driven by technological innovation, global market shifts, and mounting healthcare cost pressures. As a result, the need for cost-efficient, scalable, and reliable biologics manufacturing has never been more critical.

Enzene’s response to this challenge is EnzeneX™ 2.0 – the next evolution of our Fully-Connected Continuous Manufacturing™ (FCCM™) platform. Unlike conventional batch or semi-continuous (hybrid) processes, FCCM™ enables:

• Uninterrupted, end-to-end integration from upstream through downstream

• Elimination of inefficiencies across the production cycle

• Reduced infrastructure burden

EnzeneX™ 2.0 further enhances these advantages through:

• High-titer clones

• Advanced Process Analytical Technology (PAT)

• Optimised cell media

• Consistent, high-yield production at $40 per gram

This session will explore how platforms like FCCM™ are:

• Enabling greater yield and sustainability

• Reducing manufacturing costs

• Expanding global access to life-saving therapies

With our new FCCM-enabled facility in New Jersey, Enzene is not only expanding its global footprint but also redefining what CDMO partnerships can achieve in today’s volatile landscape.

We Are Enzene – a team of holistic thinkers, doers, and partners. We’re not just manufacturing biologics; we’re engineering a fully-connected future for how they’re made.